DSGN plans $1.72M sale of common stock via BTIG on 08/13/2025

Rhea-AI Filing Summary

Design Therapeutics filed a Form 144 reporting a proposed sale of 345,000 common shares through BTIG, LLC with an aggregate market value of $1,718,100.00. The filing lists 56,900,000 shares outstanding and shows the shares were acquired on 03/26/2021 in the open market (700,000 acquired) with cash payment.

The Form 144 indicates an approximate sale date of 08/13/2025, notes nothing to report for securities sold in the past three months, and includes the filers representation that they are not aware of any undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Routine Form 144 disclosing an intended sale of 345,000 common shares; information is factual and non-material to capital structure.

The filing documents a planned sale executed through BTIG, LLC on 08/13/2025 for an aggregate market value of $1,718,100.00. The shares were acquired on 03/26/2021 in the open market and paid for in cash. There are 56,900,000 shares outstanding reported. The notice reports no securities sold in the past three months, suggesting this is an isolated disposition rather than a pattern of recent insider selling. From a securities perspective, the disclosure is complete and procedural.

Corporate Governance Expert

TL;DR: The Form 144 is a standard compliance disclosure; it affirms the filers certification about undisclosed material information.

The document contains the required seller representations, including that the filer does not possess undisclosed material adverse information about the issuer. The filing specifies broker details (BTIG, LLC) and includes acquisition history (open market purchase on 03/26/2021). No sales in the prior three months are reported. This is a routine governance-level disclosure that meets regulatory requirements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street Fl 9 San Francisco CA 94104	345000	1718100.00	56900000	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/26/2021	Public markets	Open market			700000	03/26/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by Design Therapeutics (DSGN) disclose?

The Form 144 discloses a proposed sale of 345,000 common shares through BTIG, LLC with an aggregate market value of $1,718,100.00.

When is the approximate date of the proposed sale in the DSGN Form 144?

The Form 144 lists an approximate sale date of 08/13/2025.

How and when were the shares to be sold originally acquired?

The shares were acquired on 03/26/2021 in the open market; the filing shows 700,000 shares were acquired on that date and payment was in cash.

Does the Form 144 report any securities sold by the filer in the past three months?

No. The filing explicitly states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

What certification does the filer make in the Form 144?

The filer represents by signing the notice that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.